BeOne Medicines (ONC) Q1 2026 earnings review
Massive Operating Leverage Drives Guidance Raise, But BRUKINSA Flattens
BeOne Medicines (formerly BeiGene) delivered a blowout Q1 2026, marking a decisive reversal from its historical cash-burn phase. Total revenue reached $1.51 billion (+35% YoY), driven by its hematology workhorse, BRUKINSA. The standout story is the pure operating leverage: GAAP net income exploded to $227 million from roughly breakeven a year ago, as gross margins expanded to 89% and SG&A relative to sales shrank. Consequently, management raised FY26 revenue and operating income guidance. However, a glaring data point contradicts the unbridled optimism: sequentially, BRUKINSA's global sales stalled at $1.1 billion, raising questions about whether U.S. BTK market penetration is reaching a near-term ceiling.
🐂 Bull Case
Gross margins hit 89% while SG&A dropped to 37% of product sales (from 41% a year ago). The company is now a cash-generating machine, producing $161 million in Free Cash Flow in Q1 alone.
Raising FY26 revenue guidance by $100M to $6.3-$6.5 billion and Non-GAAP operating income to $1.45-$1.55 billion signals high management confidence in the core business and near-term pipeline rollouts.
🐻 Bear Case
While YoY growth looks phenomenal (+38%), BRUKINSA's global sales were perfectly flat at $1.1 billion compared to Q4 2025. If the primary cash cow slows down, the massive R&D pipeline becomes a heavier burden.
GAAP R&D jumped 12% YoY to $541 million as the company pushes multiple solid tumor assets (CDK4, GPC3x41BB) into pivotal Phase 3 trials. Clinical setbacks here could compress future margins.
⚖️ Verdict: 🟢
Bullish. The scale of the operating leverage and the guidance raise overshadow the sequential flattening of BRUKINSA. The company is successfully transitioning into a highly profitable, self-funding biotech giant with a deep, maturing pipeline.
Key Themes
Operating Leverage Accelerating
The margin story is the primary driver of BeOne's valuation upgrade. Gross margin on product sales jumped to 89% (up from 85.1% in 25Q1), heavily driven by the proportionally higher mix of BRUKINSA and scaled manufacturing productivity. Meanwhile, SG&A grew only 21% YoY against 34% product sales growth, causing SG&A as a percentage of sales to compress from 41% to 37%.
BRUKINSA's Sequential Growth Hits a Wall
Management heavily touted BRUKINSA's 38% YoY growth, but the absolute numbers reveal a stable, non-growing sequential trend. Global sales reported at $1.1 billion for 26Q1 are flat compared to the ~$1.1 billion reported in 25Q4. While Q1 usually carries some industry-wide seasonality and inventory drawdown, a complete halt in sequential growth for the company's foundational drug demands close monitoring in Q2.
Next-Gen Hematology Secures the Moat
To defend against BRUKINSA's eventual plateau, BeOne is aggressively executing its next-gen hematology strategy. Sonrotoclax (a BCL2 inhibitor) is now commercially available in China for R/R MCL and CLL/SLL, acting as the bridge to lucrative fixed-duration combination therapies. Concurrently, the BTK CDAC degrader (BGB-16673) is expanding its clinical footprint, initiating Phase 2 cohorts in marginal zone lymphoma (MZL) and Richter’s Transformation.
Solid Tumor Pipeline Progressing Faster Than Expected
TEVIMBRA global sales showed stable re-acceleration, reaching $206 million (+20% YoY, up from $182 million in 25Q4). Beyond TEVIMBRA, the FDA accepted an sBLA with Priority Review for TEVIMBRA combined with ZIIHERA (zanidatamab) for 1L HER2-positive GEA. The solid tumor pipeline is rapidly moving into late stages, with the CDK4 inhibitor (BGB-43395) and B7-H4 ADC (BG-C9074) both securing ASCO presentations.
R&D Expense Escalation
GAAP R&D expenses increased 12% YoY to $541 million. As BeOne pushes multiple early-stage solid tumor candidates (like the ADAM9-targeting ADC BG-C0979 and KLRG1 mAb BG-A3004) into human trials and advances BGB-B2033 into a pivotal Phase 3, these costs will likely accelerate. The company must sustain high revenue growth to prevent these clinical investments from compressing operating margins.
Macro Buffer: Inventory Buildup Continues
Total Inventories rose to $681 million from $608 million at the end of 2025. Given management's previous extensive commentary on geopolitical risks and global supply chain strategies (including an $800M US manufacturing investment), this elevated inventory likely serves as a strategic buffer against potential trade tariffs and supply chain shocks, tying up working capital.
Other KPIs
Reversing forcefully from a negative $12.3 million in Q1 2025. The company's cash conversion is highly efficient, allowing it to self-fund its massive R&D pipeline without diluting shareholders. Total cash and equivalents now sit at a fortress-like $4.85 billion.
Up 198% YoY from $8.7 million in 25Q1, reflecting the increasing cadence of milestone payments and collaboration revenues from international partners as the pipeline matures.
Guidance
Accelerating. Management raised the range from the previous $6.2 - $6.4 billion. The midpoint ($6.4B) implies a healthy 20% YoY growth compared to the $5.34 billion generated in FY25.
Accelerating. Raised from the previous range of $700 - $800 million. This demonstrates clear confidence that the margin expansion seen in Q1 (89% gross margin, lower relative SG&A) is durable throughout the year.
Stable. The range was maintained from prior guidance, meaning the entire revenue upgrade is expected to flow through to operating income. This underscores strict cost discipline.
Stable. Management maintained this outlook. Achieving 89% in Q1 perfectly aligns with the high-80% expectation, driven by BRUKINSA product mix.
Key Questions
BRUKINSA Sequential Plateau
BRUKINSA revenues were flat sequentially at $1.1 billion. How much of this is attributable to standard Q1 industry inventory drawdowns and seasonality versus an actual stabilization of new patient starts in the U.S. BTK market?
Capital Allocation and M&A
With $4.85 billion in cash and growing positive free cash flow, how does management view the balance between accelerating internal R&D, potential share buybacks, or pursuing external business development/M&A?
Sonrotoclax U.S. Trajectory
Following the launch of sonrotoclax in China, what are the specific expectations for the timing of U.S. and European regulatory filings, and how does the company plan to position it against entrenched competitors in the fixed-duration market?